Palantir CEO Alex Karp calls a job at his company 'by far the best credential in tech.' We asked recruiters if they agree.
So, do recruiters agree?
Karp has boasted on several occasions that Palantirians, as the company refers to employees, are the crème de la crème of tech workers.
"If you come to Palantir, your career is set," Karp said on Monday's earnings call. He's previously said that "no credible institution in commercial life can really be built without Palantir or an ex-Palantirian."
Palantir has minted founders and startups in droves.
Former Palantir alums have raised over $30 billion total at an average valuation of almost $800 million per company, according to AI predictive intelligence firm CB Insights. That figure is somewhat skewed by defense tech darling Anduril, which recently raised at a $30.5 billion post-money valuation in June.
Three Anduril cofounders — Trae Stephens, Matt Grimm, and Brian Schimpf — all worked at Palantir before starting Anduril alongside Palmer Luckey in 2017, according to their LinkedIn profiles.
Over 6% of founders who previously worked at Palantir started companies now worth over $1 billion, according to CB Insights.
Palantir, which reported just under 4,000 full-time employees as of December 2024, grew its revenue to $1 billion in the second quarter of 2025, a first for the company. Karp called the earnings "bombastic," and in his letter to shareholders Monday, said Palantir's skeptics have been "defanged and bent into a kind of submission." The stock is up over 600% in the last year.
So do the people hiring from the tech talent pool buy Karp's glowing view of Palantirians?
Business Insider spoke to more than half a dozen tech recruiting professionals to find out if having Palantir on your résumé is as powerful as Karp has made it sound.
The Goldman Sachs of tech
Deepali Vyas, a senior partner and global head of data, AI, and fintech at global consulting firm Korn Ferry, told BI she can "absolutely say that he's right," and she considers Palantir the Goldman Sachs of the tech industry.
"I've pulled people from Palantir," Vyas said. "They are a home run every single time."
Vyas said Palantir employees tend to work long hours, and the company has a "very hands-on culture" that allows even junior employees to work alongside the firm's "brightest minds." Having that proximity helps create a certain level of training, she added.
Vyas said another factor that makes Palantir stand out is its ability to recruit people who are passionate about their work.
"There's something in the sauce there," Vyas said. "They want to work on the complex problems because that's what excites them."
Janelle Bieler, the head of US tech talent at global tech talent and engineering company Akkodis, told Business Insider that Palantir is known for hiring elite talent and candidates that tackle complex issues. While candidates still need to be individually evaluated on what they worked on at the company, she said working at Palantir signals "intellectual horsepower."
"When a recruiter sees it on a résumé, it usually signals that this person went through a tough interview process and likely that they can hold their own in a pretty rigorous and fast-paced environment," she said.
Bieler added that Palantir's branding also stands out to recruiters. She said Palantir is neither regarded as Big Tech nor a typical startup, and the name has a level of mystique. Given the company's niche work environment, though, recruiters want to know that candidates can thrive in a variety of workplace settings.
Jason Saltzman, head of insights at CB Insights, previously told Business Insider while working at a company that tracks employment changes, that "Palantir seems to be the stop on people's career journey that accelerates them the most." Almost a quarter of former product managers at Palantir have since become founders, he said.
Ex-Palantir employees also tend to end up at a Big Tech company or "one of the hottest startups," Saltzman said. Google and Meta, as well as Anduril and OpenAI, employ many former Palantir workers, he said.
"Not only is Palantir a rubber stamp on someone's résumé that allows them to go onto whatever they do next, but also many of them want to go solve the world's biggest problems that are shaping the future as we know it, either by joining a company or starting their own," Saltzman said.
"That Palantir stamp gives the founder credibility, which makes hiring early employees easier," said Alex Klein, founding partner at Nucleus Talent. Klein's company hires partner-level venture investors and early leadership for startups. He hasn't done any work for Palantir.
"A founder or CEO who worked at Palantir for three years — even if they're 27 years old — will win the recruiting battle against the 35-year-old founder who worked at a tier two tech company," Klein added. "Palantir is absolutely a gold star on a résumé."
Some say Karp could be overstating things
Aaron Sines, director of technical recruiting at global cloud consulting firm Edison & Black, told Business Insider that while there's some truth to Karp's statement, overall he's seeing a "results revolution" among companies, where outcomes are placed above academic credentials and company names.
"My team tells me all the time results are almost always coming over academic credentials," Sines said.
Natan Fisher, the cofounder and co-CEO of tech and legal recruiting firm SingleSprout, similarly said that "execution matters more than brand," adding that "companies that want six plus days in the office are going to optimize for someone who is hungry and scrappy above all else."
"No doubt, Palantir is a strong hiring signal, but the idea of a golden ticket in tech is outdated," Fisher said. "The real hiring market doesn't reward brand names alone, it rewards execution and adaptability — who built what and scaled systems at speed."
While a gig at Palantir alone isn't necessarily a career maker, Fisher has seen an increase in tech companies hiring Forward Deployed Engineers, a job title Palantir coined for software engineers who work directly with customers.
Fisher said that tech companies often seek to hire from "multiple high-caliber" talent pools such as Ramp, Stripe, Linear, and Notion, adding that they aren't clients of his.
Sines said that Palantir has a reputation for seeking out top talent and having a "rigorous" and "results-oriented" hiring strategy. However, he said that while it carries a "badge of honor," for some clients, it may signal too much intensity for others. It depends on how companies perceive culture, Sines said.
Farah Sharghi, a job search coach and former recruiter at tech companies including Google, Lyft, Uber, and TikTok, said that while Palantir's hiring process is "very stringent," a good employee at Palantir may not be a good employee everywhere else because "there might be some nuances to some companies versus others in terms of cultural fit."
"It's really subjective relative to what the company does, what their needs are, and so on," she said.
While culture may vary across tech companies, Sharghi says the guiding philosophy when it comes to hiring is largely the same across the board.
"They're not looking for breadth of experience," she said. "They're looking for technical depth of experience."
Calling Palantir the best credential in tech, as Karp did, "flattens the reality," she added.
"Tech is broad. What makes someone a great hire at Palantir doesn't always translate to, for example, a legacy company trying to modernize systems," she said. "That takes a different skill set. There's no universal best, only fit for the problem at hand."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
13 minutes ago
- Business Wire
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC ('Melinta'), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has entered into a definitive agreement to be acquired by CorMedix Inc. ('CorMedix') (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The acquisition is a testament to the exceptional value Melinta has created through its strong portfolio, culture, capabilities, and experienced team within the hospital ecosystem for acute care. 'This acquisition represents a milestone achievement for Melinta and validates our position as a recognized leader in acute care,' said Christine Ann Miller, CEO of Melinta Therapeutics. 'I'm incredibly proud of our accomplishments. Through our talented team's dedication, we have undergone an extraordinary transformation to build a highly sought-after commercialization platform with sustainable growth and profitability. By joining forces with CorMedix, we're creating a stronger organization that will accelerate both our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision that all patients who need our therapies receive them.' Since becoming privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. in 2020, Melinta has demonstrated exceptional organizational evolution across operations, culture, and strategic positioning to achieve 85% revenue growth, positive cash flow, and sustainable profitability, while increasing employee satisfaction and building a highly talented team. Melinta has strengthened its position with global presence through ex-US partnerships and seven business development deals, including strategic partnership with BARDA to advance two FDA-approved antibiotics for use in pediatric patients, as well as the development of one product for use against biothreat pathogens. i This comprehensive evolution has established Melinta as a preferred partner who is fully integrated within the hospital ecosystem. This acquisition will expand CorMedix's commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO ® (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV ® (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate) ii. The portfolio's flagship product, REZZAYO ® is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation (BMT), which is expected to be completed in 1H2026. The addition of Melinta's high-performing team, innovative assets, and a pipeline expansion indication positions CorMedix to deliver on its ambition of becoming a leader in the specialty pharmaceutical business. 'The combination of CorMedix and Melinta represents a compelling opportunity to create a specialty pharmaceutical leader with enhanced capabilities to serve patients,' said Joseph Todisco, Chief Executive Officer of CorMedix Inc. 'Melinta's proven commercial platform and portfolio perfectly complement our own, and once combined we will have the scale, resources, and expertise to accelerate innovation while creating significant value for our stakeholders. We are thrilled to welcome the talented Melinta team and look forward to building on our shared commitment to excellence in this space.' 'Under Christine's leadership, the transformation of Melinta has been remarkable,' said Jonathan Leff, Board Member of Melinta and Partner at Deerfield Management Company. 'Through focused execution and strategic investment in its commercial capabilities, the Melinta team has built a high-performing organization that has consistently exceeded expectations. The combination with CorMedix reflects the strategic value of Melinta's infrastructure and positions the combined company for continued growth under Joe's leadership. We look forward to this next chapter.' Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay Melinta $300 million in upfront consideration (subject to customary adjustments), comprised of $260 million in cash and $40 million in CorMedix equity (in the form of pre-funded warrants) issued to Melinta shareholders. The agreement also contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix's election) for the FDA approval of REZZAYO ® for prophylaxis of invasive fungal infections in adults undergoing allogenic BMT, if the milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN ® for injection U.S. net sales. The merger is subject to customary closing conditions and U.S. regulatory approval and is expected to close in September. Advisors Evercore is acting as exclusive financial advisor and Fenwick & West LLP is acting as legal advisor to Melinta. Katten Muchin Rosenman LLP is acting as legal advisors for Deerfield Management Company, L.P. About Melinta Therapeutics Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that's how we make the most meaningful impact. At Melinta, we're visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), MINOCIN ® (minocycline) for Injection, ORBACTIV ® (oritavancin), REZZAYO ® (rezafungin for injection), TOPROL-XL ® (metoprolol succinate) and VABOMERE ® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, including their important safety information, visit About REZZAYO ® (rezafungin for injection) REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. IMPORTANT SAFETY INFORMATION REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. REZZAYO may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion. REZZAYO may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation. Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO therapy. Most common adverse reactions (incidence 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. Please see the full Prescribing Information for REZZAYO (rezafungin for injection), available at


CNN
an hour ago
- CNN
The hottest stock on Wall Street is a cryptic company you've never heard of
Tech news Investing Stocks Corporate newsFacebookTweetLink Follow After a blowout quarterly earnings report this week, Palantir has become one of the buzziest (and most expensive) stocks on Wall Street. Shares of Palantir — which we'll shorthand as a 'data analytics firm,' even though that's not even the half of it — have been on a tear. This week, the company reported its first $1 billion in quarterly revenue, beating expectations. That came just a few days after news broke that Palantir had secured a $10 billion contract from the US Army over the next decade. The stock, which several analysts say is wildly overvalued (with a market cap valuing it at around 100 times its annual revenue), has shot up nearly 600% from a year ago. With a $420 billion market valuation, Palantir is now worth more than The Walt Disney Co. and American Express combined. And yet, few outside of tech and finance have heard of it. Even fewer could tell you, without Googling, what the company actually does. (And honestly, a quick Google search doesn't come close to capturing the scope and fundamental weirdness of this 20-year-old defense-contractor-slash-commercial-artificial-intelligence-software peddler.) This is what Palantir is, and why you should care. Let's start with the name, which helps explain what the company does: 'Palantir' refers to the 'seeing stones' from 'The Lord of the Rings.' They were essentially crystal balls used for communication and intelligence-gathering. In the most generous sense, that is what Palantir's data analytics tools do: Allow users — mostly military and government agencies, but also private-sector companies — to better visualize large datasets. It promises to use its software to sift through reams of information and identify trends and patterns. In practice, that means it's enabling a lot of surveillance. By its own admission, Palantir keeps a tight lip about its clients and their activities. But we know a few things: Palantir's tech is helping the Trump administration as it tries to build a database that includes detailed portraits of Americans, gathered from multiple federal agencies, the New York Times reported in May. (Palantir disputed that reporting and said it does not 'unlawfully' surveil Americans.) That news built on a CNN report that such a database would be deployed to speed up immigration enforcement and deportations. The LAPD's use of Palantir's tech has come under scrutiny for allowing the force to engage in racial profiling and mass surveillance, according to civil rights groups. It has helped the Israel Defense Forces strike targets in Gaza. Palantir reportedly helped track down Osama bin Laden. And it reportedly helped US public health officials track the spread of Covid-19 by synthesizing data coming from local hospitals, state governments and other sources. The company was founded as a private government contractor with a mission to 'prevent the next 9/11, without sacrificing American civil liberties,' co-founder Joe Lonsdale wrote in 2020. Other co-founders include current CEO Alex Karp (more on him in a moment) and Peter Thiel, the tech billionaire, longtime Trump supporter and conservative activist known especially among elder Millennials as the guy who who made it a personal mission to destroy critical media outlets like Gawker. In its early days, Palantir struggled to secure outside investors until the CIA-backed venture firm In-Q-Tel stepped in, becoming the startup's biggest single client at the time and helping turn it into one of the most valuable private companies in America. Since going public five years ago, Palantir has leaned into its government work, particularly with the Army. 'The company has become so deeply embedded in the Defense Department that some current and former Pentagon officials said they worried about becoming overdependent on a single contractor for their data-processing needs, not unlike how the government has come to rely on Elon Musk's SpaceX for most of its space-launch needs,' according to The Wall Street Journal. And President Donald Trump himself appears to be a fan. Last month, Trump thanked Palantir CTO Shyam Sankar, among other tech leaders, at an AI conference in DC. 'We buy a lot of things from Palantir,' Trump said. 'Are we paying our bills? I think so.' Since Trump took office in January, Palantir has received more than $113 million in federal spending for work across the federal government, according to the Times. Palantir's shadowy vibes tend to be amplified by its CEO's quasi-messianic tendencies. 'Saving lives and on occasion taking lives is super interesting,' Karp told the Times last year. That echoed another comment from 2020, when he casually told Axios that Palantir's technology 'is used on occasion to kill people.' Karp is also known for his colorful language on earnings calls, fantasizing about spraying his critics with 'light fentanyl-laced urine,' in one instance. Investors don't seem to mind. 'Palantir is a mission-driven company, not for lip service's sake,' Gil Luria, the head of tech research at DA Davidson, told me. 'Dr. Karp — and he is quite vocal about this — believes that it's his goal to help protect Western civilization. And there are a lot of people that don't agree with that goal.' Some of those people include 13 of Palantir's former employees, who wrote a memo in May saying the company's founding principles have been 'violated.' Recalling the company's namesake, they wrote that the story of the seeing stones 'warned of great dangers when wielded by those without wisdom or a moral compass, as they could be used to distort truth and present selective visions of reality.' Palantir's leadership has 'abandoned its founding ideals,' including a commitment to transparency, free speech, privacy protections and ethical data practices, the letter said. 'By supporting Trump's administration, Elon Musk's DOGE initiative, and dangerous expansions of executive power, they have abandoned their responsibility.' Karp took a moment to dunk on his critics this week. 'This is a once in a generation, truly anomalous quarter,' he said. 'We're very proud. And we're sorry that our haters are disappointed.'


CNN
an hour ago
- CNN
The hottest stock on Wall Street is a cryptic company you've never heard of
After a blowout quarterly earnings report this week, Palantir has become one of the buzziest (and most expensive) stocks on Wall Street. Shares of Palantir — which we'll shorthand as a 'data analytics firm,' even though that's not even the half of it — have been on a tear. This week, the company reported its first $1 billion in quarterly revenue, beating expectations. That came just a few days after news broke that Palantir had secured a $10 billion contract from the US Army over the next decade. The stock, which several analysts say is wildly overvalued (with a market cap valuing it at around 100 times its annual revenue), has shot up nearly 600% from a year ago. With a $420 billion market valuation, Palantir is now worth more than The Walt Disney Co. and American Express combined. And yet, few outside of tech and finance have heard of it. Even fewer could tell you, without Googling, what the company actually does. (And honestly, a quick Google search doesn't come close to capturing the scope and fundamental weirdness of this 20-year-old defense-contractor-slash-commercial-artificial-intelligence-software peddler.) This is what Palantir is, and why you should care. Let's start with the name, which helps explain what the company does: 'Palantir' refers to the 'seeing stones' from 'The Lord of the Rings.' They were essentially crystal balls used for communication and intelligence-gathering. In the most generous sense, that is what Palantir's data analytics tools do: Allow users — mostly military and government agencies, but also private-sector companies — to better visualize large datasets. It promises to use its software to sift through reams of information and identify trends and patterns. In practice, that means it's enabling a lot of surveillance. By its own admission, Palantir keeps a tight lip about its clients and their activities. But we know a few things: Palantir's tech is helping the Trump administration as it tries to build a database that includes detailed portraits of Americans, gathered from multiple federal agencies, the New York Times reported in May. (Palantir disputed that reporting and said it does not 'unlawfully' surveil Americans.) That news built on a CNN report that such a database would be deployed to speed up immigration enforcement and deportations. The LAPD's use of Palantir's tech has come under scrutiny for allowing the force to engage in racial profiling and mass surveillance, according to civil rights groups. It has helped the Israel Defense Forces strike targets in Gaza. Palantir reportedly helped track down Osama bin Laden. And it reportedly helped US public health officials track the spread of Covid-19 by synthesizing data coming from local hospitals, state governments and other sources. The company was founded as a private government contractor with a mission to 'prevent the next 9/11, without sacrificing American civil liberties,' co-founder Joe Lonsdale wrote in 2020. Other co-founders include current CEO Alex Karp (more on him in a moment) and Peter Thiel, the tech billionaire, longtime Trump supporter and conservative activist known especially among elder Millennials as the guy who who made it a personal mission to destroy critical media outlets like Gawker. In its early days, Palantir struggled to secure outside investors until the CIA-backed venture firm In-Q-Tel stepped in, becoming the startup's biggest single client at the time and helping turn it into one of the most valuable private companies in America. Since going public five years ago, Palantir has leaned into its government work, particularly with the Army. 'The company has become so deeply embedded in the Defense Department that some current and former Pentagon officials said they worried about becoming overdependent on a single contractor for their data-processing needs, not unlike how the government has come to rely on Elon Musk's SpaceX for most of its space-launch needs,' according to The Wall Street Journal. And President Donald Trump himself appears to be a fan. Last month, Trump thanked Palantir CTO Shyam Sankar, among other tech leaders, at an AI conference in DC. 'We buy a lot of things from Palantir,' Trump said. 'Are we paying our bills? I think so.' Since Trump took office in January, Palantir has received more than $113 million in federal spending for work across the federal government, according to the Times. Palantir's shadowy vibes tend to be amplified by its CEO's quasi-messianic tendencies. 'Saving lives and on occasion taking lives is super interesting,' Karp told the Times last year. That echoed another comment from 2020, when he casually told Axios that Palantir's technology 'is used on occasion to kill people.' Karp is also known for his colorful language on earnings calls, fantasizing about spraying his critics with 'light fentanyl-laced urine,' in one instance. Investors don't seem to mind. 'Palantir is a mission-driven company, not for lip service's sake,' Gil Luria, the head of tech research at DA Davidson, told me. 'Dr. Karp — and he is quite vocal about this — believes that it's his goal to help protect Western civilization. And there are a lot of people that don't agree with that goal.' Some of those people include 13 of Palantir's former employees, who wrote a memo in May saying the company's founding principles have been 'violated.' Recalling the company's namesake, they wrote that the story of the seeing stones 'warned of great dangers when wielded by those without wisdom or a moral compass, as they could be used to distort truth and present selective visions of reality.' Palantir's leadership has 'abandoned its founding ideals,' including a commitment to transparency, free speech, privacy protections and ethical data practices, the letter said. 'By supporting Trump's administration, Elon Musk's DOGE initiative, and dangerous expansions of executive power, they have abandoned their responsibility.' Karp took a moment to dunk on his critics this week. 'This is a once in a generation, truly anomalous quarter,' he said. 'We're very proud. And we're sorry that our haters are disappointed.'